June 3 (Reuters) - Pulmatrix Inc ::SABBY MANAGEMENT LLC REPORTS 5.19% PASSIVE STAKE IN PULMATRIX INC AS OF MAY 30 - SEC FILING.
Full Article
May 16 (Reuters) - Pulmatrix Inc ::PULMATRIX ANNOUNCES LEADERSHIP CHANGE.PULMATRIX INC - DR. ROBERT CLARKE HAS STEPPED DOWN AS CHIEF EXECUTIVE OFFICER.PULMATRIX INC - TED RAAD WILL IMMEDIATELY TRANSITION FROM HIS CURRENT ROLE AS CHIEF BUSINESS OFFICER TO THAT OF CHIEF EXECUTIVE OFFICER.PULMATRIX INC - CLARKE WILL CONTINUE AS ADVISOR TO BOARD AND MANAGEMENT THROUGH AUGUST 14, 2019.
Full Article
May 15 (Reuters) - Pulmatrix Inc ::PULMATRIX REPORTS Q1 2019 RESULTS.PULMATRIX INC - GENERATED NO REVENUE IN Q1 OF 2019, COMPARED TO $0.2 MILLION OF REVENUES IN Q1 OF 2018.PULMATRIX INC QTRLY LOSS PER SHARE $0.74.PULMATRIX INC - AS OF MARCH 31, 2019, PULMATRIX HAD $2.1 MILLION IN CASH, COMPARED TO $2.6 MILLION AS OF DECEMBER 31, 2018.
Full Article
Feb 19 (Reuters) - Pulmatrix Inc ::PULMATRIX REPORTS 2018 FINANCIAL RESULTS; PROVIDES 2019 OUTLOOK ON PULMONARY DISEASE PIPELINE.PULMATRIX INC - PREPARING FOR PULMAZOLE PHASE 2 TRIAL THAT CO EXPECTS TO BEGIN IN FIRST HALF OF 2019.
Full Article
Dec 28 (Reuters) - Pulmatrix Inc ::PULMATRIX INC FILES FOR SECONDARY OFFERING OF COMMON UNITS OF UPTO $25 MILLION.
Full Article
Pulmatrix Inc ::PULMATRIX REPORTS Q3 2018 RESULTS.PULMATRIX INC - QTRLY LOSS PER SHARE $0.10.PULMATRIX INC - PLAN TO INITIATE PHASE 2 CLINICAL TRIAL OF PULMAZOLE IN PATIENTS WITH ASTHMA AND ABPA NEXT MONTH.PULMATRIX INC - AS OF SEPTEMBER 30, 2018, PULMATRIX HAD $3.8 MILLION IN CASH AND CASH EQUIVALENTS, COMPARED TO $3.6 MILLION AS OF DECEMBER 31, 2017.
Full Article
May 11 (Reuters) - Pulmatrix Inc ::PULMATRIX REPORTS Q1 2018 RESULTS.Q1 REVENUE $200,000.QTRLY LOSS PER SHARE $0.24.
Full Article
March 13 (Reuters) - Pulmatrix Inc ::PULMATRIX REPORTS 2017 FINANCIAL RESULTS; PROVIDES 2018 OUTLOOK ON PULMONARY DISEASE PIPELINE.PULMATRIX INC - PHASE 2A STUDY EXPECTED TO BEGIN IN Q4-2018 FOR PULMAZOLE.PULMATRIX INC - EXPECT NON-CLINICAL SAFETY DATA ON PUR1800 IN SECOND HALF OF 2018.PULMATRIX INC - FY NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS $0.93 .
Full Article
Nov 9 (Reuters) - Pulmatrix Inc :Pulmatrix provides Q3 2017 highlights and Q3 2017 updated financials.Q3 revenue $300,000 versus $100,000.Qtrly net loss per share attributable to common stockholders $0.22.As of September 30, 2017, Pulmatrix had $6.4 million in cash and cash equivalents, compared to $4.2 million as of December 31, 2016.
Full Article
Aug 4 (Reuters) - Pulmatrix Inc :Pulmatrix provides 2017 company year-to-date highlights and q2 2017 updated financials.Generated no revenues in Q2 of 2017, compared to $0.3 million for Q2 of 2016.Qtrly loss per share $0.29.Decreased qtrly revenue directly related to conclusion of clinical study funded under collaboration agreement to develop PUR0200 for COPD.As of June 30, 2017, Pulmatrix had $11.0 million in cash and cash equivalents, compared to $4.2 million as of December 31, 2016.
Full Article
Earnings vs. 
Estimates